| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 15th December 2020 | Mark A Sirgo | 230,769 | Open or private purchase | $0.65 | $149,999.85 |
| 15th December 2020 | John Temperato | 153,846 | Open or private purchase | $0.65 | $99,999.90 |
| 15th December 2020 | Edward J Sitar | 61,538 | Open or private purchase | $0.65 | $39,999.70 |
| 2nd December 2020 | Israel Gp Ltd. Orbi Med | 103,200 | Open or private sale | $21.60 | $2,229,120.00 |
| 27th November 2020 | John Temperato | 203,667 | Grant/award etc. | $0.00 | |
| 9th November 2020 | Lorin K Johnson | 4,262 | Exercise of in-the-money or at-the-money derivatives securities (usually options) | $4.00 | $17,048.00 |
| 30th October 2020 | Israel Gp Ltd. Orbi Med | 1,943,734 | Other acquisition or disposition | $0.00 | |
| 30th October 2020 | Nissim Darvish | 1,943,734 | Other acquisition or disposition | $0.00 | |
| 30th October 2020 | Mark A Sirgo | 4,513 | Other acquisition or disposition | $0.00 | |
| 30th October 2020 | John Temperato | 4,513 | Other acquisition or disposition | $0.00 |
9 Meters Biopharma
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Innovate Biopharmaceuticals, Inc. is a clinical-stage biopharm Pharmaceutical company. The company is founded by Jay P. Madan and Kendyle Woodard in 2012.
Ticker: INNT
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1551986
Employees: 8
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.